Skip to main content
Article
Licensed
Unlicensed Requires Authentication

Two hours of urine output are a reliable parameter for intravenous furosemide adequacy and the need for doubling dose in acute heart failure: a prospective study

  • ORCID logo EMAIL logo , ORCID logo , ORCID logo , ORCID logo , ORCID logo , ORCID logo , , ORCID logo and ORCID logo
Published/Copyright: January 23, 2026

Abstract

Objectives

This study compared urine output at 2 and 6 h post-furosemide and explored factors influencing diuretic efficacy in acute heart failure (AHF).

Methods

A prospective study (June–August 2023) included AHF patients (≥18 years) with NT-proBNP ≥300 pg/mL. Urinary spot sodium and urine output were measured at baseline, 2, and 6 h after 40 mg IV furosemide.

Results

Among 32 patients, 26 (81.25 %) had satisfactory urine output, and 30 (93.75 %) met the target urinary sodium concentration at 2 h. No significant difference in mean urine output was found between the 2 and 6 h intervals (267 ± 189 mL vs. 298 ± 149 mL, p=0.099). Urine output correlated strongly with urinary sodium concentration (p < 0.001, R2=0.683). Serum creatinine was a significant predictor of urine output (p=0.007).

Conclusions

The comparable urine output at 2 and 6 h suggests that a 2 h assessment may be sufficient to evaluate diuretic response and guide dose adjustments in AHF.


Corresponding author: Mochamad Y. Alsagaff, MD, PhD, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga—Dr. Soetomo General Hospital, Mayjen Prof. Dr. Moestopo Street No. 47, 60132, Surabaya, Indonesia; and Universitas Airlangga Hospital, Surabaya 60115, Indonesia, E-mail:

  1. Research ethics: The local Institutional Review Board deemed the study exempt from review (UA-02-23083).

  2. Informed consent: Informed consent was obtained from all individuals included in this study, or their legal guardians or wards.

  3. Author contributions: MYA and RNDA were involved in concepting and planning the research. RNDA, WPN, and DMN performed the data acquisition/collection. RNDA, WPN, and DMN calculated the experimental data and performed the analysis. RNDA, MYA and YA drafted the manuscript and designed the figures. MYA, HS, CP, LFKW, and IM aided in interpreting the results. All authors took parts in giving critical revision of the manuscript.

  4. Use of Large Language Models, AI and Machine Learning Tools: None declared.

  5. Conflict of interest: All other authors state no conflict of interest.

  6. Research funding: None declared.

  7. Data availability: All data generated or analyzed during this study were included in this published article. The corresponding author (M.Y.A.) can be contacted for more information.

References

1. McDonagh, TA, Metra, M, Adamo, M, Gardner, RS, Baumbach, A, Böhm, M, et al.. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368.Search in Google Scholar PubMed

2. Wu, L, Rodriguez, M, El Hachem, K, Krittanawong, C. Diuretic treatment in heart failure: a practical guide for clinicians. J Clin Med 2024;13:4470. https://doi.org/10.3390/jcm13154470.Search in Google Scholar PubMed PubMed Central

3. Suri, SS, Pamboukian, SV. Optimal diuretic strategies in heart failure. Ann Transl Med 2021;9. https://doi.org/10.21037/atm-20-4600.Search in Google Scholar PubMed PubMed Central

4. Matsue, Y, Damman, K, Voors, AA, Kagiyama, N, Yamaguchi, T, Kuroda, S, et al.. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol 2017;69:3042–51. https://doi.org/10.1016/j.jacc.2017.04.042.Search in Google Scholar PubMed

5. Park, JJ, Kim, SH, Oh, IY, Choi, DJ, Park, HA, Cho, HJ, et al.. The effect of door-to-diuretic time on clinical outcomes in patients with acute heart failure. JACC Heart Fail 2018;6:286–94. https://doi.org/10.1016/j.jchf.2017.12.017.Search in Google Scholar PubMed

6. Testani, JM, Brisco, MA, Turner, JM, Spatz, ES, Bellumkonda, L, Parikh, CR, et al.. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail 2014;7:261–70. https://doi.org/10.1161/circheartfailure.113.000895.Search in Google Scholar

7. Verbrugge, FH, Nijst, P, Dupont, M, Penders, J, Tang, WHW, Mullens, W. Urinary composition during decongestive treatment in heart failure with reduced ejection fraction. Circ Heart Fail 2014;7:766–72. https://doi.org/10.1161/circheartfailure.114.001377.Search in Google Scholar PubMed

8. Felker, GM, Lee, KL, Bull, DA, Redfield, MM, Stevenson, LW, Goldsmith, SR, et al.. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797–805. https://doi.org/10.1056/nejmoa1005419.Search in Google Scholar PubMed PubMed Central

9. Hodson, DZ, Griffin, M, Mahoney, D, Raghavendra, P, Ahmad, T, Turner, J, et al.. Natriuretic response is highly variable and associated with 6 month survival: insights from the ROSE-AHF trial. JACC Heart Fail 2019;7:383–91. https://doi.org/10.1016/j.jchf.2019.01.007.Search in Google Scholar PubMed PubMed Central

10. Singh, D, Shrestha, K, Testani, JM, Verbrugge, FH, Dupont, M, Mullens, W, et al.. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. J Card Fail 2014;20:392–9. https://doi.org/10.1016/j.cardfail.2014.06.116.Search in Google Scholar

Received: 2025-03-15
Accepted: 2025-11-12
Published Online: 2026-01-23

© 2025 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 22.4.2026 from https://www.degruyterbrill.com/document/doi/10.1515/jbcpp-2025-0041/html
Scroll to top button